Oxaliplatin desensitization for ovarian cancer in pregnancy: A case report

Kaitlin Nicholson; Lily Jia; Margaret Rowe; Katharine Esselen; Naima Joseph; Chloe A Zera; Timothy Lax; Meghan Shea

doi:10.1016/j.gore.2024.101354

Oxaliplatin desensitization for ovarian cancer in pregnancy: A case report

Gynecol Oncol Rep. 2024 Feb 28:52:101354. doi: 10.1016/j.gore.2024.101354. eCollection 2024 Apr.

Authors

Kaitlin Nicholson^{1

2}, Lily Jia^{2

3}, Margaret Rowe⁴, Katharine Esselen^{1

2}, Naima Joseph⁵, Chloe A Zera^{1

2}, Timothy Lax⁶, Meghan Shea⁷

Affiliations

¹ Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
² Harvard Medical School, Boston, MA, United States.
³ Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, United States.
⁴ Department of Medicine, Penn Medicine, Philadelphia, PA, United States.
⁵ Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Boston Medical Center/Boston University, Boston, MA, United States.
⁶ Department of Medicine, University of Massachusetts Memorial Health, Worcester, MA, United States.
⁷ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.

Abstract

•Incidence of cancer in pregnancy is rising and successful treatment of these patients requires expert multidisciplinary care.•Platinum hypersensitivity reactions in ovarian cancer are commonly treated with desensitization protocols.•To our knowledge, chemotherapy desensitization in pregnant patients has not been previously reported.•Oxaliplatin desensitization during pregnancy may be safe and feasible.

Keywords: Desensitization; Hypersensitivity reaction; Ovarian cancer; Platinum chemotherapy.

Publication types

Case Reports